Articles from EMulate Therapeutics, Inc.

New study published in Journal of Electromagnetic Biology and Medicine provides additional validation for Company’s technology and business model

Revolutionary ulRFE® Technology Demonstrates Promising Results in Brain Cancer, Mental Health, and Pain Management Without Traditional Drugs or their Side Effects

EMulate Therapeutics, Inc. (“Emulate”) announces the Open Journal of Biophysics (OJBIPHY), publisher of over 200 peer-reviewed open access journals, has accepted its manuscript, titled “Magnetic Field Emulations of Small Inhibitor RNA: Effects on Implanted GL261 Tumors in C57BL/6 Immune Competent Mice” for publication. This submission supports independent results in an animal model of Glioblastoma Multiforme (GBM), recently published by Mukthavaram et al. (Bioelectron Med 2024 Vol. 10 Issue 1 Pages 10), which demonstrates the ability of EMulate’s second signal treatment offering, A2. GBM is a rare brain glioma that currently has no established treatment on the market and is categorized by the U.S. Food and Drug Administration (FDA) as a highly underserved orphan disease (affects fewer than 200,000 in the U.S.). https://www.scirp.org/journal/paperinformation?paperid=135320

EMulate Therapeutics, Inc. (EMulate) announces the peer-reviewed publication titled, “Evaluation of the EMulate Therapeutics’ Ultra-Low Radiofrequency Energy (ulRFE®) Device in Murine Model of Glioblastoma (GBM)” in BMC Bioelectronic Medicine. The authors of the paper (Rajesh Mukthavaram; Pengfei Jiang; Sandra Pastorino; Natsuko Nomura; Feng Lin; Santosh Kesari) tested the effectiveness of the emulation of EMulate’s ulRFE signal of paclitaxel (A1A) and the immune checkpoint inhibitor ulRFE signal targeting immune checkpoints CTLA-4 and PD-1 (A2) in a murine GBM model.

EMulate Therapeutics, Inc. (EMTx) proudly announced today the acceptance of their abstract for presentation and publication in the 28th Annual Meeting and Education Day of the Society for Neuro-Oncology (SNO), November 2023, in Vancouver, British Columbia. The accepted abstract will be published in SNO’s official journal, Neuro-Oncology, which is now available at https://academic.oup.com/neuro-oncology/supplements.

EMulate Therapeutics, Inc. (EMulate) announced today the publication of its peer-reviewed clinical trial using EMulate’s technology for the treatment of glioblastoma in the Journal CNS Oncology https://www.futuremedicine.com/doi/10.2217/cns-2022-0016. This marks an ongoing and developing pathway in the development of EMulate’s oncology treatment business.

EMulate Therapeutics, Inc. (“EMulate” or the “Company”) is excited to announce that Brett J. Greene will be a new advisor to the Company. He will focus his attention on the Company’s work in mental health therapeutics.

EMulate Therapeutics Has Incorporated A New Wholly Owned Subsidiary to Deploy Its Platform Technology for the Treatment of Cancer. BELLEVUE, WA / ACCESSWIRE / February 23, 2022 / EMulate Therapeutics, Inc., a clinical-stage therapeutic device company focused on developing and commercializing innovative and distinctive therapies to address critical unmet needs in healthcare, today announced the incorporation of a third wholly owned subsidiary,